STAFFORD, Texas (PRWEB)
September 06, 2019
WhiteHill Life Science LLC announces that its most recent National Stage filing of its patent WO 218/236539 A 1 can unlock methods to combat the opioid crisis.
“The opioid crisis is not hopeless, nor must it be without end. Recent court decisions and settlements surrounding prescription opioids underscore the need for solutions that can be implemented now, not years from now, and are easy to administer and at low cost,” from Ron Butler, CEO.
Our scientific team lead by Dr. Dale Brown PhD engaged in research for several years that culminated in a patent filed with a priority date of June 20, 2017 and an international filing through WIPO (World Intellectual Property Organization) May 28, 2018. That pending patent titled Synergistic Compositions and Methods of Achieving Homeostasis in Mammalian Systems was moved to National Stage filing in the US recently. It has been published and can be accessed as WO 218/236539 A1.
Dr. Brown explains, “We know that pain, inflammatory diseases and conditions, even addictions, can be interdicted via the ionotropic cannabinoid channels by certain artificial and natural compositions. We have demonstrated in our recently published pending patent filing, that a simple device like a lozenge slowly dissolving in the mouth can deliver non-prescription pain relief without any addictive properties found in various cannabis products. The FDA scrutiny of CBD and cannabis-based products is timely and much needed to protect users. There are implications for Alzheimer’s based on observations of enhanced cannabinoid receptors of the Alzheimer’s brain. We focus on alternatives that are simple and straightforward based on sound science,” said Dr. Brown.
“Not all corporate decisions have to be about optimizing profits for shareholders. There are stakeholders in every community that can benefit from this discovery,” said Mr. Butler.
Those interested in discussing our Intellectual Property can contact senior management at WhiteHill: inquiries(at)WHLifeSciences(dot)com
Share article on social media or email: